Notable Call Buying Activity Continues in Celgene (CELG) Following Reported Acquisition of Juno Therapeutics (JUNO) -Susquehanna

Celgene (CELG) PT Lowered to $117 at BofA/Merrill Lynch Following Juno (JUNO) Acquisition

January 22, 2018 11:12 AM EST

BofA/Merrill Lynch lowered its price target on Celgene (NASDAQ: CELG) to $117.00 (from $120.00) while maintaining a Neutral rating.

... More

Stocks hit record as senators reach deal to end shutdown

January 22, 2018 7:39 AM EST

By Chuck Mikolajczak

(Reuters) - U.S. stocks advanced on Monday as each of Wall Street's main scored records in the wake of a deal by U.S. senators to end the federal government shutdown.

Legislation to renew federal funding to the government cleared a procedural hurdle in the Senate and was expected soon to pass votes in the Senate and House of Representatives, allowing government to re-open through Feb 8.

"You would think something like the threat of a government shutdown or an actual government shutdown would serve as a catalyst to spook some weaker... More

Biotech Sector on Watch After Two Major Deals Announced (IBB)

January 22, 2018 6:57 AM EST

Biotech stocks were in focus prior to the market open Monday after two major deals were announced. Sanofi (NYSE: SNY) and Bioverativ Inc. (NASDAQ: BIVV) entered into a merger agreement valued at $11.6 billion. Celgene Corporation (NASDAQ:... More

Celgene (CELG) volatility elevated into acquiring Juno Therapeutics for approximately $87 per share in cash

January 22, 2018 6:51 AM EST

Celgene (NASDAQ: CELG) January weekly call option implied volatility is at 46, February is at 33; compared to its 52-week range of 17 to 38 into acquiring Juno Therapeutics (JUNO) for approximately $87 per share in cash.

... More

Remaining CAR-T Stocks on Watch Following JUNO/CELG

January 22, 2018 6:46 AM EST

Remaining CAR-T stocks are on watch after Juno Therapeutics (NASDAQ: JUNO) agreed to be acquired by Celgene (NASDAQ: CELG) for $87/share.

bluebird bio (NASDAQ: BLUE)Bellicum Pharma (NASDAQ: BLCM)Cellectis (NASDAQ: CLLS)Adaptimmune Therapeutics (NASDAQ: ADAP)CRISPR Therapeutics (NASDAQ: CRSP)Editas Medicine (NASDAQ: EDIT)... More

Celgene (CELG) to Acquire Juno Therapeutics (JUNO) for $87/Share

January 22, 2018 6:30 AM EST

Celgene Corporation (NASDAQ: CELG) and Juno Therapeutics, Inc. (NASDAQ: JUNO) today announced the signing of a definitive merger agreement in which Celgene has agreed to acquire Juno. Under the terms of the merger agreement, Celgene will pay $87 per share in cash, or a total of approximately $9 billion, net of cash and marketable securities acquired and Juno shares already owned by Celgene (approximately 9.7% of outstanding shares). The transaction was approved by the boards of directors of both companies.

Juno is a pioneer in the development of... More

Celgene (CELG) Reports Investigational Data Evaluating ABRAXANE Regimen for Patients with Locally Advanced Pancreatic Cancer

January 22, 2018 5:40 AM EST

Celgene Corporation (NASDAQ: CELG) today announced primary endpoint findings and updated results of secondary endpoints from the phase II international LAPACT trial of ABRAXANE® (paclitaxel protein-bound particles for injectable suspension) (albumin-bound) plus gemcitabine in patients with locally advanced pancreatic cancer. The results were presented today at the 2018 American Society of Clinical Oncology Gastrointestinal Cancers Symposium (ASCO GI) in San Francisco, California.

An analysis of patients with newly diagnosed, locally advanced pancreatic cancer treated with up to 6 cycles of ABRAXANE + gemcitabine as an investigational induction therapy (n=106) found that patients had a median time to... More